Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $577.4 million.

  • Dianthus Therapeutics' Liabilities and Shareholders Equity rose 6300.59% to $577.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 2653.82%. This contributed to the annual value of $374.0 million for FY2024, which is 10847.13% up from last year.
  • Dianthus Therapeutics' Liabilities and Shareholders Equity amounted to $577.4 million in Q3 2025, which was up 6300.59% from $326.1 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Liabilities and Shareholders Equity peaked at $577.4 million during Q3 2025, and registered a low of $78.6 million during Q2 2023.
  • Moreover, its 4-year median value for Liabilities and Shareholders Equity was $194.4 million (2022), whereas its average is $258.8 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Liabilities and Shareholders Equity plummeted by 5707.44% in 2023, and later soared by 36918.67% in 2024.
  • Dianthus Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $83.1 million in 2022, then skyrocketed by 115.86% to $179.4 million in 2023, then soared by 108.47% to $374.0 million in 2024, then skyrocketed by 54.39% to $577.4 million in 2025.
  • Its last three reported values are $577.4 million in Q3 2025, $326.1 million for Q2 2025, and $348.6 million during Q1 2025.